CO2025009079A2 - Procedimientos para mejorar la farmacocinética de migalastat - Google Patents
Procedimientos para mejorar la farmacocinética de migalastatInfo
- Publication number
- CO2025009079A2 CO2025009079A2 CONC2025/0009079A CO2025009079A CO2025009079A2 CO 2025009079 A2 CO2025009079 A2 CO 2025009079A2 CO 2025009079 A CO2025009079 A CO 2025009079A CO 2025009079 A2 CO2025009079 A2 CO 2025009079A2
- Authority
- CO
- Colombia
- Prior art keywords
- migalastat
- pharmacokinetics
- procedures
- improve
- limiting
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263432235P | 2022-12-13 | 2022-12-13 | |
| US18/315,928 US20240197706A1 (en) | 2022-12-13 | 2023-05-11 | Methods of improving the pharmacokinetics of migalastat |
| PCT/US2023/067656 WO2024129220A1 (en) | 2022-12-13 | 2023-05-31 | Methods of improving the pharmacokinetics of migalastat |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2025009079A2 true CO2025009079A2 (es) | 2025-09-29 |
Family
ID=86646511
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2025/0009079A CO2025009079A2 (es) | 2022-12-13 | 2025-07-03 | Procedimientos para mejorar la farmacocinética de migalastat |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20240197706A1 (enExample) |
| EP (2) | EP4667050A2 (enExample) |
| JP (1) | JP7757345B2 (enExample) |
| KR (1) | KR20240094973A (enExample) |
| AU (1) | AU2023396459A1 (enExample) |
| CA (1) | CA3201512A1 (enExample) |
| CL (1) | CL2025001743A1 (enExample) |
| CO (1) | CO2025009079A2 (enExample) |
| DE (1) | DE202023003007U1 (enExample) |
| DK (1) | DK4385509T3 (enExample) |
| FI (1) | FI4385509T3 (enExample) |
| IL (1) | IL321404A (enExample) |
| MX (1) | MX2025006897A (enExample) |
| PT (1) | PT4385509T (enExample) |
| TW (1) | TW202423436A (enExample) |
| WO (1) | WO2024129220A1 (enExample) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6274597B1 (en) | 1998-06-01 | 2001-08-14 | Mount Sinai School Of Medicine Of New York University | Method of enhancing lysosomal α-Galactosidase A |
| AU2008232614A1 (en) | 2007-03-30 | 2008-10-09 | Amicus Therapeutics, Inc. | Method for the treatment of Fabry disease using pharmacological chaperones |
| US9999618B2 (en) * | 2007-04-26 | 2018-06-19 | Amicus Therapeutics, Inc. | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones |
| DK3470077T3 (da) | 2008-02-12 | 2020-11-30 | Amicus Therapeutics Inc | Fremgangsmåde til forudsigelse af respons på behandling af sygdomme med farmakologiske chaperoner |
| SG193379A1 (en) * | 2011-03-11 | 2013-10-30 | Amicus Therapeutics Inc | Dosing regimens for the treatment of fabry disease |
| WO2023081781A1 (en) * | 2021-11-03 | 2023-05-11 | Sangamo Therapeutics, Inc. | Methods for use of viral vector constructs for the treatment of fabry disease |
-
2023
- 2023-05-11 US US18/315,928 patent/US20240197706A1/en active Pending
- 2023-05-31 KR KR1020230070371A patent/KR20240094973A/ko not_active Ceased
- 2023-05-31 JP JP2023090210A patent/JP7757345B2/ja active Active
- 2023-05-31 WO PCT/US2023/067656 patent/WO2024129220A1/en not_active Ceased
- 2023-05-31 DK DK23176366.5T patent/DK4385509T3/da active
- 2023-05-31 TW TW112120343A patent/TW202423436A/zh unknown
- 2023-05-31 IL IL321404A patent/IL321404A/en unknown
- 2023-05-31 EP EP25199386.1A patent/EP4667050A2/en active Pending
- 2023-05-31 CA CA3201512A patent/CA3201512A1/en active Pending
- 2023-05-31 DE DE202023003007.2U patent/DE202023003007U1/de active Active
- 2023-05-31 EP EP23176366.5A patent/EP4385509B1/en active Active
- 2023-05-31 PT PT231763665T patent/PT4385509T/pt unknown
- 2023-05-31 AU AU2023396459A patent/AU2023396459A1/en active Pending
- 2023-05-31 FI FIEP23176366.5T patent/FI4385509T3/fi active
-
2025
- 2025-06-12 CL CL2025001743A patent/CL2025001743A1/es unknown
- 2025-06-12 MX MX2025006897A patent/MX2025006897A/es unknown
- 2025-07-03 CO CONC2025/0009079A patent/CO2025009079A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP7757345B2 (ja) | 2025-10-21 |
| JP2024084670A (ja) | 2024-06-25 |
| DE202023003007U1 (de) | 2025-07-21 |
| US20240197706A1 (en) | 2024-06-20 |
| MX2025006897A (es) | 2025-07-01 |
| CL2025001743A1 (es) | 2025-10-03 |
| KR20240094973A (ko) | 2024-06-25 |
| TW202423436A (zh) | 2024-06-16 |
| CA3201512A1 (en) | 2024-06-13 |
| FI4385509T3 (fi) | 2025-12-05 |
| WO2024129220A1 (en) | 2024-06-20 |
| AU2023396459A1 (en) | 2025-06-26 |
| DK4385509T3 (da) | 2025-12-08 |
| EP4385509B1 (en) | 2025-09-03 |
| EP4385509A1 (en) | 2024-06-19 |
| PT4385509T (pt) | 2025-11-25 |
| EP4667050A2 (en) | 2025-12-24 |
| IL321404A (en) | 2025-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2022000278A (es) | Inhibidores de cisteína proteasas y sus métodos de uso | |
| EA202190006A1 (ru) | Пуриноновые соединения и их применение при лечении рака | |
| MX2020007014A (es) | Compuestos de benzamida. | |
| EA201590999A1 (ru) | Пирролобензодиазепины и их конъюгаты | |
| CO2021004789A2 (es) | Piridazinonas y sus métodos de uso | |
| EA201991894A1 (ru) | ПИПЕРИДИН-ЗАМЕЩЕННЫЕ ИНГИБИТОРЫ Mnk И СВЯЗАННЫЕ С НИМИ СПОСОБЫ | |
| EA201991399A1 (ru) | Аминотриазолопиридиновые соединения и их применение в лечении рака | |
| EA202193015A1 (ru) | Ингибиторы cdk | |
| CR20200334A (es) | Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas | |
| CY1117776T1 (el) | Εναντιομερη ενωσεων σπειρο-οξινδολιου και οι χρησεις τους ως θεραπευτικοι παραγοντες | |
| EA201791289A1 (ru) | Ингибиторы клеточного некроза и связанные с ними способы | |
| MX2016014248A (es) | Compuestos polifluorados que actuan como inhibidores de la tirosina cinasa de bruton. | |
| EA201790078A1 (ru) | Ингибиторы mnk и связанные с ними способы | |
| EA202192905A1 (ru) | Соединения, содержащие n-метил-2-пиридон, и фармацевтически приемлемые соли | |
| EA202092558A1 (ru) | КРИСТАЛЛИЧЕСКАЯ ФОРМА ИНГИБИТОРА c-MET, ЕГО СОЛЕВАЯ ФОРМА И СПОСОБ ИХ ПОЛУЧЕНИЯ | |
| CO2024010803A2 (es) | Compuestos de tienopirrolotriazina, su preparación y su uso terapéutico | |
| EA202091604A1 (ru) | Ингибирование ионного канала a1 с транзиторным рецепторным потенциалом | |
| MX2021014524A (es) | Metodos para tratar canceres del sistema urinario. | |
| CL2020000471A1 (es) | Regímenes de tratamiento. | |
| BR112018011196A2 (pt) | uso de pirimido-pirimidazinonas para tratar o câncer | |
| CR20200649A (es) | Agosnistas de tlr7 | |
| EA201590656A1 (ru) | Азаиндолины | |
| MX2022003270A (es) | Compuesto de amida heterocíclica, sal farmacéuticamente aceptable delmismo y método de preparación y uso del mismo. | |
| CO2025009079A2 (es) | Procedimientos para mejorar la farmacocinética de migalastat | |
| AR129487A1 (es) | Métodos para mejorar la farmacocinética de migalastat |